{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:31:10Z","timestamp":1793399470050,"version":"4.5.0"},"reference-count":215,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-02955-8","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:32:28Z","timestamp":1784953948000},"page":"3279-3301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic kidney disease: from mineral dysregulation to bone and cardiovascular disease"],"prefix":"10.1007","volume":"49","author":[{"given":"Melpomeni","family":"Moustaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula A.","family":"Paschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Palioura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Kassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Symeon","family":"Tournis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andromachi","family":"Vryonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"4S","key":"2955_CR1","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ et al (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105(4S):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"2955_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP (2022) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 12:7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003","journal-title":"Kidney Int Suppl"},{"key":"2955_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-21851-z","volume":"25","author":"L Deng","year":"2025","unstructured":"Deng L, Guo S, Liu Y et al (2025) Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021. BMC Public Health 25:636. https:\/\/doi.org\/10.1186\/s12889-025-21851-z","journal-title":"BMC Public Health"},{"key":"2955_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2022.101641","volume":"17","author":"G Eknoyan","year":"2022","unstructured":"Eknoyan G, Moe SM (2022) Renal osteodystrophy: A historical review of its origins and conceptual evolution. Bone Rep 17:101641. https:\/\/doi.org\/10.1016\/j.bonr.2022.101641","journal-title":"Bone Rep"},{"key":"2955_CR5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J et al (2006) Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945\u20131953. https:\/\/doi.org\/10.1038\/sj.ki.5000414","journal-title":"Kidney Int"},{"key":"2955_CR6","first-page":"1","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017) KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 7:1\u201359","journal-title":"Kidney Int Suppl"},{"key":"2955_CR7","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/ndt\/gft514","volume":"29","author":"M Cozzolino","year":"2014","unstructured":"Cozzolino M, Ure\u00f1a-Torres P, Vervloet MG et al (2014) Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol Dial Transplant 29:1815\u20131820. https:\/\/doi.org\/10.1093\/ndt\/gft514","journal-title":"Nephrol Dial Transplant"},{"key":"2955_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","volume":"107","author":"M Ketteler","year":"2025","unstructured":"Ketteler M, Evenepoel P, Holden RM et al (2025) Chronic kidney disease\u2013mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 107:405\u2013423. https:\/\/doi.org\/10.1016\/j.kint.2024.11.013","journal-title":"Kidney Int."},{"key":"2955_CR9","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/ndt\/gfw073","volume":"31","author":"D Hansen","year":"2016","unstructured":"Hansen D, Olesen JB, Gislason GH, Abrahamsen B, Hommel K (2016) Risk of fracture in adults on renal replacement therapy: A Danish national cohort study. Nephrol Dial Transplant 31:1654\u20131662. https:\/\/doi.org\/10.1093\/ndt\/gfw073","journal-title":"Nephrol Dial Transplant"},{"key":"2955_CR10","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.2215\/CJN.04260413","volume":"8","author":"GA Block","year":"2013","unstructured":"Block GA, Kilpatrick RD, Lowe KA, Wang W, Danese MD (2013) CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol 8:2132\u20132140. https:\/\/doi.org\/10.2215\/CJN.04260413","journal-title":"Clin J Am Soc Nephrol"},{"key":"2955_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4103\/aam.aam_18_19","volume":"18","author":"A Abdu","year":"2019","unstructured":"Abdu A, Abdu A, Arogundade F (2019) Prevalence and pattern of chronic kidney disease-mineral bone disorders among hemodialysis patients in Kano, northwest Nigeria. Ann Afr Med 18:191\u2013195. https:\/\/doi.org\/10.4103\/aam.aam_18_19","journal-title":"Ann Afr Med"},{"key":"2955_CR12","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.ekir.2020.02.118","volume":"5","author":"VO Ndu","year":"2020","unstructured":"Ndu VO, Wokoma FS, Emem-Chioma PC, Oko-Jaja RI, David-West M, Fakrogha PE (2020) Prevalence, pattern and characteristics of CKD-MBD in Rivers State Nigeria. Kidney Int Rep 5:S48\u2013S49. https:\/\/doi.org\/10.1016\/j.ekir.2020.02.118","journal-title":"Kidney Int Rep"},{"key":"2955_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.11622\/smedj.2015195","volume":"57","author":"SH Chuang","year":"2016","unstructured":"Chuang SH, Wong HC, Vathsala A, Lee E, How PPC (2016) Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes. Singapore Med J 57:603\u2013609. https:\/\/doi.org\/10.11622\/smedj.2015195","journal-title":"Singapore Med J"},{"key":"2955_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s10157-024-02562-y","volume":"29","author":"Y Imanishi","year":"2025","unstructured":"Imanishi Y, Taniuchi S, Kodama S et al (2025) Real-world fracture risk, osteoporosis treatment status, and mortality of Japanese non-dialysis patients with chronic kidney disease stages G3\u20135. Clin Exp Nephrol 29:236\u2013247. https:\/\/doi.org\/10.1007\/s10157-024-02562-y","journal-title":"Clin Exp Nephrol"},{"key":"2955_CR15","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","volume":"30","author":"JL Fernandez-Martin","year":"2015","unstructured":"Fernandez-Martin JL, Martinez-Camblor P, Dionisi MP et al (2015) Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: The COSMOS study. Nephrol Dial Transpl 30:1542\u20131551. https:\/\/doi.org\/10.1093\/ndt\/gfv099","journal-title":"Nephrol Dial Transpl"},{"key":"2955_CR16","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.3390\/JCM14134567","volume":"14","author":"SJ Schunk","year":"2025","unstructured":"Schunk SJ, Zimmermann P (2025) Cardiovascular Risk and its Presentation in Chronic Kidney Disease. J Clin Med 14:4567. https:\/\/doi.org\/10.3390\/JCM14134567","journal-title":"J Clin Med"},{"key":"2955_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s12020-021-02735-9","volume":"73","author":"G Hampson","year":"2021","unstructured":"Hampson G, Elder GJ, Cohen-Solal M, Abrahamsen B (2021) A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. Endocrine 73:509\u2013529. https:\/\/doi.org\/10.1007\/s12020-021-02735-9","journal-title":"Endocrine"},{"key":"2955_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11914-025-00919-0","volume":"23","author":"MR Laurent","year":"2025","unstructured":"Laurent MR, Dupont J, Lemahieu W et al (2025) Treatment of Osteoporosis in Patients with Chronic Kidney Disease. Curr Osteoporos Rep 23:26. https:\/\/doi.org\/10.1007\/s11914-025-00919-0","journal-title":"Curr Osteoporos Rep"},{"key":"2955_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40266-019-00696-3","volume":"36","author":"A Galassi","year":"2019","unstructured":"Galassi A, Ciceri P, Fasulo E, Carugo S, Cianciolo G, Cozzolino M (2019) Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly. Drugs Aging 36:885\u2013895. https:\/\/doi.org\/10.1007\/s40266-019-00696-3","journal-title":"Drugs Aging"},{"key":"2955_CR20","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS et al (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370\u20131378. https:\/\/doi.org\/10.1038\/ki.2011.47","journal-title":"Kidney Int"},{"key":"2955_CR21","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","volume":"64","author":"T Larsson","year":"2003","unstructured":"Larsson T, Nisbeth U, Ljunggren O, Uppner HJ, Jonsson KB (2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272\u20132279. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00328.x","journal-title":"Kidney Int"},{"key":"2955_CR22","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s11255-016-1379-8","volume":"48","author":"W Lv","year":"2016","unstructured":"Lv W, Guan L, Zhang Y, Yu S, Cao B, Ji Y (2016) Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4. Int Urol Nephrol 48:2043\u20132050. https:\/\/doi.org\/10.1007\/s11255-016-1379-8","journal-title":"Int Urol Nephrol"},{"key":"2955_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176411","author":"GJ Behets","year":"2017","unstructured":"Behets GJ, Viaene L, Meijers B et al (2017) Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0176411","journal-title":"PLoS One"},{"key":"2955_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cca.2019.12.008","volume":"502","author":"A Bouquegneau","year":"2020","unstructured":"Bouquegneau A, Evenepoel P, Paquot F, Malaise O, Cavalier E, Delanaye P (2020) Sclerostin within the chronic kidney disease spectrum. Clin Chim Acta 502:84\u201390. https:\/\/doi.org\/10.1016\/j.cca.2019.12.008","journal-title":"Clin Chim Acta"},{"key":"2955_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00223-020-00665-8","volume":"108","author":"J Bacchetta","year":"2020","unstructured":"Bacchetta J, Bernardor J, Garnier C, Naud C, Ranchin B (2020) Hyperphosphatemia and Chronic Kidney Disease: A Major Daily Concern Both in Adults and in Children. Calcif Tissue Int 108:116\u2013127. https:\/\/doi.org\/10.1007\/s00223-020-00665-8","journal-title":"Calcif Tissue Int"},{"key":"2955_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biom12081157","author":"I Alesutan","year":"2022","unstructured":"Alesutan I, Henze LA, Boehme B et al (2022) Periostin augments vascular smooth muscle cell calcification via \u03b2-catenin signaling. Biomolecules. https:\/\/doi.org\/10.3390\/biom12081157","journal-title":"Biomolecules"},{"key":"2955_CR27","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.kint.2018.08.011","volume":"94","author":"RC Pereira","year":"2018","unstructured":"Pereira RC, Salusky IB, Roschger P et al (2018) Impaired osteocyte maturation in the pathogenesis of renal osteodystrophy. Kidney Int 94:1002\u20131012. https:\/\/doi.org\/10.1016\/j.kint.2018.08.011","journal-title":"Kidney Int"},{"key":"2955_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1177829","volume":"14","author":"A Aguilar","year":"2023","unstructured":"Aguilar A, Gifre L, Ure\u00f1a-Torres P et al (2023) Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis. Front Physiol 14:1177829. https:\/\/doi.org\/10.3389\/fphys.2023.1177829","journal-title":"Front Physiol"},{"key":"2955_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1210\/jc.2013-2786","volume":"99","author":"D Cejka","year":"2014","unstructured":"Cejka D, Marculescu R, Kozakowski N et al (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99:248\u2013255. https:\/\/doi.org\/10.1210\/jc.2013-2786","journal-title":"J Clin Endocrinol Metab"},{"key":"2955_CR30","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00198-014-2934-8","volume":"26","author":"Y Asamiya","year":"2015","unstructured":"Asamiya Y, Yajima A, Shimizu S, Otsubo S, Tsuchiya K, Nitta K (2015) Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level. Osteoporos Int 26:1017\u20131028. https:\/\/doi.org\/10.1007\/s00198-014-2934-8","journal-title":"Osteoporos Int"},{"key":"2955_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3265\/Nefrologia.pre2012.Nov.11703","volume":"33","author":"JL G\u00f3rriz","year":"2013","unstructured":"G\u00f3rriz JL, Molina P, Bover J et al (2013) Characteristics of bone mineral metabolism in patients with stage 3\u20135 chronic kidney disease not on dialysis: Results of the OSERCE study. Nefrologia 33:46\u201360. https:\/\/doi.org\/10.3265\/Nefrologia.pre2012.Nov.11703","journal-title":"Nefrologia"},{"key":"2955_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1053\/j.ajkd.2019.07.022","volume":"75","author":"T Isakova","year":"2020","unstructured":"Isakova T, Cai X, Lee J et al (2020) Longitudinal evolution of markers of mineral metabolism in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 75:235\u2013244. https:\/\/doi.org\/10.1053\/j.ajkd.2019.07.022","journal-title":"Am J Kidney Dis"},{"key":"2955_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M et al (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31\u201338. https:\/\/doi.org\/10.1038\/sj.ki.5002009","journal-title":"Kidney Int"},{"key":"2955_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-14","volume":"14","author":"K Chartsrisak","year":"2013","unstructured":"Chartsrisak K, Vipattawat K, Assanatham M et al (2013) Mineral metabolism and outcomes in chronic kidney disease stage 2\u20134 patients. BMC Nephrol 14:14. https:\/\/doi.org\/10.1186\/1471-2369-14-14","journal-title":"BMC Nephrol"},{"key":"2955_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-206","volume":"14","author":"B Satirapoj","year":"2013","unstructured":"Satirapoj B, Limwannata P, Chaiprasert A, Supasyndh O, Choovichian P (2013) Vitamin D insufficiency and deficiency with stages of chronic kidney disease in an Asian population. BMC Nephrol 14:206. https:\/\/doi.org\/10.1186\/1471-2369-14-206","journal-title":"BMC Nephrol"},{"key":"2955_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20503121221148613","volume":"11","author":"MR Abdul Razzaque","year":"2023","unstructured":"Abdul Razzaque MR, Tebha SS, Tukruna A et al (2023) 25-Hydroxyvitamin-D deficiency in chronic kidney disease stages III, IV, and V in South Asian population: a retrospective cohort. SAGE Open Med 11:1\u20136. https:\/\/doi.org\/10.1177\/20503121221148613","journal-title":"SAGE Open Med"},{"key":"2955_CR37","doi-asserted-by":"publisher","unstructured":"Restrepo Valencia CA, Aguirre Arango JV (2016) Vitamin D (25(OH)D) in patients with chronic kidney disease stages 2\u20135. Colomb Med 166. https:\/\/doi.org\/10.25100\/cm.v50i1.4444","DOI":"10.25100\/cm.v50i1.4444"},{"key":"2955_CR38","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.transproceed.2015.04.036","volume":"47","author":"E \u00c7ankaya","year":"2015","unstructured":"\u00c7ankaya E, Bilen Y, Kele\u015f M et al (2015) Comparison of Serum Vitamin D Levels among Patients with Chronic Kidney Disease, Patients in Dialysis, and Renal Transplant Patients. Transplant Proc 47:1405\u20131407. https:\/\/doi.org\/10.1016\/j.transproceed.2015.04.036","journal-title":"Transplant Proc"},{"key":"2955_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00223-021-00844-1","volume":"109","author":"M Christodoulou","year":"2021","unstructured":"Christodoulou M, Aspray TJ, Schoenmakers I (2021) Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines. Calcif Tissue Int 109:157\u2013178. https:\/\/doi.org\/10.1007\/s00223-021-00844-1","journal-title":"Calcif Tissue Int"},{"key":"2955_CR40","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/jn\/114.7.1313","volume":"114","author":"AI Jacob","year":"1984","unstructured":"Jacob AI, Sallman A, Santiz Z, Hollis\u2019\u00e3\u017e AW (1984) Defective Photoproduction of Cholecalciferol in Normal and Uremic Humans. J Nutr 114:1313\u20131319. https:\/\/doi.org\/10.1093\/jn\/114.7.1313","journal-title":"J Nutr"},{"key":"2955_CR41","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1681\/ASN.2009080815","volume":"21","author":"J Michaud","year":"2010","unstructured":"Michaud J, Naud J, Ouimet D et al (2010) Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol 21:1488\u20131497. https:\/\/doi.org\/10.1681\/ASN.2009080815","journal-title":"J Am Soc Nephrol"},{"key":"2955_CR42","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.nefro.2020.12.019","volume":"41","author":"J Bover","year":"2021","unstructured":"Bover J, Arana C, Ure\u00f1a P et al (2021) Hiporrespuesta o resistencia a la acci\u00f3n de la hormona paratiroidea en la enfermedad renal cr\u00f3nica. Nefrologia 41:514\u2013528. https:\/\/doi.org\/10.1016\/j.nefro.2020.12.019","journal-title":"Nefrologia"},{"key":"2955_CR43","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1053\/j.ajkd.2007.12.018","volume":"51","author":"JA Vassalotti","year":"2008","unstructured":"Vassalotti JA, Uribarri J, Chen SC et al (2008) Trends in Mineral Metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999\u20132004. Am J Kidney Dis 51:S56\u2013S68. https:\/\/doi.org\/10.1053\/j.ajkd.2007.12.018","journal-title":"Am J Kidney Dis"},{"key":"2955_CR44","doi-asserted-by":"publisher","unstructured":"Hruska KA, Teitelbaum SL (1995) Renal Osteodystrophy. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJM199507203330307","DOI":"10.1056\/NEJM199507203330307"},{"key":"2955_CR45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.22540\/JRPMS-08-122","volume":"8","author":"SG Moschonas","year":"2024","unstructured":"Moschonas SG, Tournis S (2024) Tertiary Hyperparathyroidism: A Review of The Disease. J Res Pract Musculoskelet Syst 8:122\u2013133. https:\/\/doi.org\/10.22540\/JRPMS-08-122","journal-title":"J Res Pract Musculoskelet Syst"},{"key":"2955_CR46","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2215\/CJN.10390917","volume":"13","author":"WL Lau","year":"2018","unstructured":"Lau WL, Obi Y, Kalantar-Zadeh K (2018) Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol 13:952\u2013961. https:\/\/doi.org\/10.2215\/CJN.10390917","journal-title":"Clin J Am Soc Nephrol"},{"key":"2955_CR47","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1210\/jc.2013-2975","volume":"98","author":"PS Parfrey","year":"2013","unstructured":"Parfrey PS, Chertow GM, Block GA et al (2013) The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: The Evolve Trial. J Clin Endocrinol Metab 98:4834\u20134844. https:\/\/doi.org\/10.1210\/jc.2013-2975","journal-title":"J Clin Endocrinol Metab"},{"key":"2955_CR48","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/ki.2010.260","volume":"78","author":"T Krajisnik","year":"2020","unstructured":"Krajisnik T, Olauson H, Mirza MAI et al (2020) Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 78:1024\u20131032. https:\/\/doi.org\/10.1038\/ki.2010.260","journal-title":"Kidney Int"},{"key":"2955_CR49","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1172\/JCI114931","volume":"86","author":"T Naveh-Many","year":"1990","unstructured":"Naveh-Many T, Marx R, Keshet E, Pike JW, Silver J (1990) Regulation of 1,25-Dihydroxyvitamin D3 Receptor Gene Expression by 1 ,25-Dihydroxyvitamin D3 in the Parathyroid In Vivo. J Clin Invest 86:1968\u20131975","journal-title":"J Clin Invest"},{"key":"2955_CR50","doi-asserted-by":"publisher","first-page":"30337","DOI":"10.1074\/jbc.M201804200","volume":"277","author":"L Canaff","year":"2002","unstructured":"Canaff L, Hendy GN (2002) Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 277:30337\u201330350. https:\/\/doi.org\/10.1074\/jbc.M201804200","journal-title":"J Biol Chem"},{"key":"2955_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1159\/000489747","volume":"43","author":"AE Grzegorzewska","year":"2018","unstructured":"Grzegorzewska AE, Bednarski D, \u015awiderska M, Mostowska A, Jagodzi\u0144ski PP (2018) The Calcium-Sensing Receptor Gene Polymorphism rs1801725 and Calcium-Related Phenotypes in Hemodialysis Patients. Kidney Blood Press Res 43:719\u2013734. https:\/\/doi.org\/10.1159\/000489747","journal-title":"Kidney Blood Press Res"},{"key":"2955_CR52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12882-018-0831-7","volume":"19","author":"B Waziri","year":"2018","unstructured":"Waziri B, Dix-Peek T, Dickens C, Duarte R, Naicker S (2018) Influence of Vitamin D receptor polymorphisms on biochemical markers of mineral bone disorders in South African patients with chronic kidney disease. BMC Nephrol 19:30. https:\/\/doi.org\/10.1186\/s12882-018-0831-7","journal-title":"BMC Nephrol"},{"key":"2955_CR53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/0886022X.2016.1256310","volume":"39","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Zhang LL, Ding FX, Cao P, Qi YY, Wang J (2017) Pin1 and secondary hyperparathyroidism of chronic kidney disease: Gene polymorphisms and protein levels. Ren Fail 39:159\u2013165. https:\/\/doi.org\/10.1080\/0886022X.2016.1256310","journal-title":"Ren Fail"},{"key":"2955_CR54","doi-asserted-by":"publisher","first-page":"100417","DOI":"10.1016\/j.omsc.2025.100417","volume":"11","author":"AH Salloum","year":"2025","unstructured":"Salloum AH, Khadro N, Ali I, Assad M, Alshehabi Z (2025) The trinity of chronic kidney failure, hyperparathyroidism, and brown tumors: a case report. Oral Maxillofac Surg Cases 11:100417. https:\/\/doi.org\/10.1016\/j.omsc.2025.100417","journal-title":"Oral Maxillofac Surg Cases"},{"key":"2955_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.surg.2021.03.067","volume":"171","author":"W Sutton","year":"2022","unstructured":"Sutton W, Chen X, Patel P et al (2022) Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients. Surg (United States) 171:69\u201376. https:\/\/doi.org\/10.1016\/j.surg.2021.03.067","journal-title":"Surg (United States)"},{"key":"2955_CR56","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/SLA.0000000000005946","volume":"278","author":"R Wang","year":"2023","unstructured":"Wang R, Price G, Disharoon M et al (2023) Resolution of Secondary Hyperparathyroidism After Kidney Transplantation and the Effect on Graft Survival. Ann Surg 278:366\u2013375. https:\/\/doi.org\/10.1097\/SLA.0000000000005946","journal-title":"Ann Surg"},{"key":"2955_CR57","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jss.2022.02.011","volume":"276","author":"KM Ramonell","year":"2022","unstructured":"Ramonell KM, Lindeman B, Chen H, Fazendin J (2022) Parathyroidectomy for Normocalcemic Tertiary Hyperparathyroidism: A 19-Year Experience. J Surg Res 276:362\u2013368. https:\/\/doi.org\/10.1016\/j.jss.2022.02.011","journal-title":"J Surg Res"},{"key":"2955_CR58","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00423-018-1726-6","volume":"403","author":"WY van der Plas","year":"2018","unstructured":"van der Plas WY, Dulfer RR, Koh EY et al (2018) Safety and efficacy of subtotal or total parathyroidectomy for patients with secondary or tertiary hyperparathyroidism in four academic centers in the Netherlands. Langenbecks Arch Surg 403:999\u20131005. https:\/\/doi.org\/10.1007\/s00423-018-1726-6","journal-title":"Langenbecks Arch Surg"},{"key":"2955_CR59","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.kint.2021.04.043","volume":"100","author":"M Haarhaus","year":"2021","unstructured":"Haarhaus M, Evenepoel P (2021) Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int 100:546\u2013558. https:\/\/doi.org\/10.1016\/j.kint.2021.04.043","journal-title":"Kidney Int"},{"key":"2955_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237130","author":"E Nagy","year":"2022","unstructured":"Nagy E, Sobh MM, Abdalbary M et al (2022) Is Adynamic Bone Always a Disease? Lessons from Patients with Chronic Kidney Disease. J Clin Med 11. https:\/\/doi.org\/10.3390\/jcm11237130","journal-title":"J Clin Med 11"},{"key":"2955_CR61","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00198-025-07647-2","volume":"36","author":"V Siampanopoulou","year":"2025","unstructured":"Siampanopoulou V, Ziogas DC, Lyrarakis G et al (2025) Bone mineral density changes following immune checkpoint inhibitor therapy: insights from a case series analysis. Osteoporos Int 36:1711\u20131718. https:\/\/doi.org\/10.1007\/s00198-025-07647-2","journal-title":"Osteoporos Int"},{"key":"2955_CR62","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.ekir.2022.02.022","volume":"7","author":"A El-Husseini","year":"2022","unstructured":"El-Husseini A, Abdalbary M, Lima F et al (2022) Low Turnover Renal Osteodystrophy with Abnormal Bone Quality and Vascular Calcification in Patients with Mild-to-Moderate CKD. Kidney Int Rep 7:1016\u20131026. https:\/\/doi.org\/10.1016\/j.ekir.2022.02.022","journal-title":"Kidney Int Rep"},{"key":"2955_CR63","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/oxfordjournals.ndt.a027404","volume":"11","author":"G Coen","year":"1996","unstructured":"Coen G, Mazzaferro S, Ballanti P et al (1996) Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transpl 11:813\u2013819. https:\/\/doi.org\/10.1093\/oxfordjournals.ndt.a027404","journal-title":"Nephrol Dial Transpl"},{"key":"2955_CR64","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jcte.2016.07.002","volume":"5","author":"SK Sista","year":"2016","unstructured":"Sista SK, Arum SM (2016) Management of adynamic bone disease in chronic kidney disease: A brief review. J Clin Transl Endocrinol 5:32\u201335. https:\/\/doi.org\/10.1016\/j.jcte.2016.07.002","journal-title":"J Clin Transl Endocrinol"},{"key":"2955_CR65","doi-asserted-by":"publisher","DOI":"10.1023\/a:1020146023812","author":"E Carlstedt","year":"1999","unstructured":"Carlstedt E, Ridefelt P, Lind L, Rastad J (1999) Interleukin-6 induced suppression of bovine parathyroid hormone secretion. Biosci Rep. https:\/\/doi.org\/10.1023\/a:1020146023812","journal-title":"Biosci Rep"},{"key":"2955_CR66","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/ki.1990.144","volume":"37","author":"T Sugimoto","year":"1990","unstructured":"Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E (1990) Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int 37:1522\u20131527. https:\/\/doi.org\/10.1038\/ki.1990.144","journal-title":"Kidney Int"},{"key":"2955_CR67","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s11914-016-0332-1","volume":"14","author":"M Yamamoto","year":"2016","unstructured":"Yamamoto M, Sugimoto T (2016) Advanced Glycation End Products, Diabetes, and Bone Strength. Curr Osteoporos Rep 14:320\u2013326. https:\/\/doi.org\/10.1007\/s11914-016-0332-1","journal-title":"Curr Osteoporos Rep"},{"key":"2955_CR68","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.3390\/jcm10194617","volume":"10","author":"L Dalle Carbonare","year":"2021","unstructured":"Dalle Carbonare L, Valenti MT, Giannini S et al (2021) Bone biopsy for histomorphometry in chronic kidney disease (CKD): State-of\u2010the\u2010art and new perspectives. J Clin Med 10:4617. https:\/\/doi.org\/10.3390\/jcm10194617","journal-title":"J Clin Med"},{"key":"2955_CR69","doi-asserted-by":"publisher","first-page":"894","DOI":"10.2215\/CJN.09950818","volume":"14","author":"S Keronen","year":"2019","unstructured":"Keronen S, Martola L, Finne P, Burton IS, Kr\u00f6ger H, Honkanen E (2019) Changes in bone histomorphometry after kidney transplantation. Clin J Am Soc Nephrol 14:894\u2013903. https:\/\/doi.org\/10.2215\/CJN.09950818","journal-title":"Clin J Am Soc Nephrol"},{"key":"2955_CR70","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.kint.2016.10.008","volume":"91","author":"P Evenepoel","year":"2017","unstructured":"Evenepoel P, Behets GJ, Viaene L, D\u2019Haese PC (2017) Bone histomorphometry in de novo renal transplant recipients indicates a further decline in bone resorption 1 year post transplantation. Kidney Int 91:469\u2013476. https:\/\/doi.org\/10.1016\/j.kint.2016.10.008","journal-title":"Kidney Int"},{"key":"2955_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164107","volume":"15","author":"D Santoso","year":"2023","unstructured":"Santoso D, Thaha M, Empitu MA et al (2023) Brown tumour in chronic kidney disease: revisiting an old disease with a new perspective. Cancers (Basel) 15:4107. https:\/\/doi.org\/10.3390\/cancers15164107","journal-title":"Cancers (Basel)"},{"key":"2955_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/endocr\/bqad022","volume":"164","author":"T Hasegawa","year":"2023","unstructured":"Hasegawa T, Tokunaga S, Yamamoto T et al (2023) Evocalcet rescues secondary hyperparathyroidism-driven cortical porosity in CKD male rats. Endocrinology 164:1\u201317. https:\/\/doi.org\/10.1210\/endocr\/bqad022","journal-title":"Endocrinology"},{"key":"2955_CR73","doi-asserted-by":"publisher","DOI":"10.1259\/dmfr.20190253","volume":"49","author":"J Wang","year":"2019","unstructured":"Wang J, Zhao X, Shi H, Zhu L, Tao X (2019) Radiological diagnostic features of uremic leontiasis ossea: a case report. Dentomaxillofac Radiol 49:20190253. https:\/\/doi.org\/10.1259\/dmfr.20190253","journal-title":"Dentomaxillofac Radiol"},{"key":"2955_CR74","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12020-019-01976-z","volume":"65","author":"WM Luchi","year":"2019","unstructured":"Luchi WM, Vianna JGP, Roberto LEV, Boas EAV, Costalonga EF (2019) Uremic leontiasis ossea. Endocrine 65:707\u2013709. https:\/\/doi.org\/10.1007\/s12020-019-01976-z","journal-title":"Endocrine"},{"key":"2955_CR75","first-page":"810","volume":"44","author":"M Ardalan","year":"2011","unstructured":"Ardalan M, Azabdaftari N, Noshad H, Shoja MM (2011) Hypophosphatemia in peritoneal dialysis patients. Saudi J Kidney Dis Transpl 44:810\u2013811","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"2955_CR76","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1053\/j.ajkd.2017.03.015","volume":"70","author":"MR Hanudel","year":"2017","unstructured":"Hanudel MR, Froch L, Gales B, J\u00fcppner H, Salusky IB (2017) Fractures and osteomalacia in a patient treated with frequent home hemodialysis. Am J Kidney Dis 70:445\u2013448. https:\/\/doi.org\/10.1053\/j.ajkd.2017.03.015","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2955_CR77","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12882-021-02509-5","volume":"22","author":"M Hatano","year":"2021","unstructured":"Hatano M, Kitajima I, Yamamoto S et al (2021) Case report: osteomalacia due to bisphosphonate treatment in a patient on hemodialysis. BMC Nephrol 22:298. https:\/\/doi.org\/10.1186\/s12882-021-02509-5","journal-title":"BMC Nephrol"},{"key":"2955_CR78","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00198-023-06886-5","volume":"34","author":"E Elkhouli","year":"2023","unstructured":"Elkhouli E, Nagy E, Santos CGS et al (2023) Mixed uremic osteodystrophy: an ill-described common bone pathology in patients with chronic kidney disease. Osteoporos Int 34:2003\u20132012. https:\/\/doi.org\/10.1007\/s00198-023-06886-5","journal-title":"Osteoporos Int"},{"key":"2955_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-0968.2005.222_8_8.x","volume":"9","author":"M Legan","year":"2005","unstructured":"Legan M, Benedik M, Kova\u010d D, C\u00f6r A (2005) 8 mixed uremic osteodystrophy \u2013 a predominant form of renal bone disease in Slovenia. Ther Apher Dial 9:80. https:\/\/doi.org\/10.1111\/j.1526-0968.2005.222_8_8.x","journal-title":"Ther Apher Dial"},{"key":"2955_CR80","doi-asserted-by":"publisher","first-page":"e20230119","DOI":"10.1590\/2175","volume":"46","author":"CE Moraes Carbonara","year":"2024","unstructured":"Moraes Carbonara CE, Barreto J, Vieira Roza NA et al (2024) Renal osteodystrophy and clinical outcomes: a prospective cohort study. Braz J Nephrol 46:e20230119. https:\/\/doi.org\/10.1590\/2175","journal-title":"Braz J Nephrol"},{"key":"2955_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031859","volume":"25","author":"JW Teh","year":"2024","unstructured":"Teh JW, Mac Gearailt C, Lappin DWP (2024) Post-transplant bone disease in kidney transplant recipients: diagnosis and management. Int J Mol Sci 25:1859. https:\/\/doi.org\/10.3390\/ijms25031859","journal-title":"Int J Mol Sci"},{"key":"2955_CR82","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1093\/ndt\/gfab239","volume":"36","author":"HS J\u00f8rgensen","year":"2021","unstructured":"J\u00f8rgensen HS, Behets G, Bammens B et al (2021) Patterns of renal osteodystrophy 1 year after kidney transplantation. Nephrol Dial Transplant 36:2130\u20132139. https:\/\/doi.org\/10.1093\/ndt\/gfab239","journal-title":"Nephrol Dial Transplant"},{"key":"2955_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15070460","volume":"15","author":"G Gembillo","year":"2025","unstructured":"Gembillo G, Sessa C, Morale W et al (2025) Fracture risk in chronic kidney disease: addressing an overlooked complication. Metabolites 15:460. https:\/\/doi.org\/10.3390\/metabo15070460","journal-title":"Metabolites"},{"key":"2955_CR84","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40620-016-0339-9","volume":"29","author":"C Carvalho","year":"2016","unstructured":"Carvalho C, Alves CM, Fraz\u00e3o JM (2016) The role of bone biopsy for the diagnosis of renal osteodystrophy: a short overview and future perspectives. J Nephrol 29:617\u2013626. https:\/\/doi.org\/10.1007\/s40620-016-0339-9","journal-title":"J Nephrol"},{"key":"2955_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13671","volume":"33","author":"M Chandran","year":"2019","unstructured":"Chandran M, Hao Y, Kwee AK et al (2019) Addressing bone quality and bone density after renal transplantation: a prospective evaluation of the evolution of trabecular bone score and bone mineral density over the first 5 years following renal transplantation in Asian patients. Clin Transplant 33:00e13671. https:\/\/doi.org\/10.1111\/ctr.13671","journal-title":"Clin Transplant"},{"key":"2955_CR86","doi-asserted-by":"publisher","unstructured":"Fernandes Diz Lopes M, Cardoso Fernandes BJ, Almeida e Sousa MT et al (2025) The impact of bone histomorphometry, bone-related biomarkers, and FRAX on fractures patients with predialysis CKD. Braz J Nephrol 47: e20240276. https:\/\/doi.org\/10.1590\/2175-8239-JBN-2024-0276en","DOI":"10.1590\/2175-8239-JBN-2024-0276en"},{"key":"2955_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115188","author":"J Przedlacki","year":"2020","unstructured":"Przedlacki J, Buczy\u0144ska-Chyl J, Ko\u017ami\u0144ski P et al (2020) FRAX prognostic and intervention thresholds in the management of major bone fractures in hemodialysis patients: a two-year prospective multicenter cohort study. Bone. https:\/\/doi.org\/10.1016\/j.bone.2019.115188","journal-title":"Bone."},{"key":"2955_CR88","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/jbmr.3669","volume":"34","author":"B Lentle","year":"2019","unstructured":"Lentle B, Koromani F, Brown JP et al (2019) The Radiology of Osteoporotic Vertebral Fractures Revisited. J Bone MinerRes 34:409\u2013418. https:\/\/doi.org\/10.1002\/jbmr.3669","journal-title":"J Bone MinerRes"},{"key":"2955_CR89","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.rcl.2010.02.018","volume":"48","author":"D Diacinti","year":"2010","unstructured":"Diacinti D, Guglielmi G (2010) Vertebral Morphometry. Radiol Clin North Am 48:561\u2013575. https:\/\/doi.org\/10.1016\/j.rcl.2010.02.018","journal-title":"Radiol Clin North Am"},{"key":"2955_CR90","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-025-02741-y","author":"B Pellegrini","year":"2025","unstructured":"Pellegrini B, Cantaluppi V, Aimaretti G et al (2025) Awareness of post-transplant endocrine disorders among kidney transplant clinicians: results of an Italian survey. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-025-02741-y","journal-title":"J Endocrinol Invest"},{"key":"2955_CR91","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00198-025-07422-3","volume":"36","author":"HP Bhattoa","year":"2025","unstructured":"Bhattoa HP, Vasikaran S, Trifonidi I et al (2025) Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Osteoporos Int 36:579\u2013608. https:\/\/doi.org\/10.1007\/s00198-025-07422-3","journal-title":"Osteoporos Int"},{"key":"2955_CR92","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00198-019-05033-3","volume":"30","author":"S Geng","year":"2019","unstructured":"Geng S, Kuang Z, Peissig PL, Page D, Maursetter L, Hansen KE (2019) Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease. Osteoporos Int 30:2019\u20132025. https:\/\/doi.org\/10.1007\/s00198-019-05033-3","journal-title":"Osteoporos Int"},{"key":"2955_CR93","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1016\/j.ekir.2024.07.008","volume":"9","author":"H Komaba","year":"2024","unstructured":"Komaba H, Imaizumi T, Hamano T (2024) Lower Parathyroid Hormone Levels are Associated with Reduced Fracture Risk in Japanese Patients on Hemodialysis. Kidney Int Rep 9:2956\u20132969. https:\/\/doi.org\/10.1016\/j.ekir.2024.07.008","journal-title":"Kidney Int Rep"},{"key":"2955_CR94","doi-asserted-by":"publisher","first-page":"6306","DOI":"10.3390\/jcm12196306","volume":"12","author":"M Fusaro","year":"2023","unstructured":"Fusaro M, Pereira L, Bover J (2023) Current and Emerging Markers and Tools Used in the Diagnosis and Management of Chronic Kidney Disease\u2013Mineral and Bone Disorder in Non-Dialysis Adult Patients. J Clin Med 12:6306. https:\/\/doi.org\/10.3390\/jcm12196306","journal-title":"J Clin Med"},{"key":"2955_CR95","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s00223-024-01275-4","volume":"115","author":"L Aaltonen","year":"2024","unstructured":"Aaltonen L, Hellman T, Lankinen R, Hakam\u00e4ki M, Mets\u00e4rinne K, J\u00e4rvisalo M (2024) Cardiac Biomarkers are Associated with Incident Fracture Risk in Advanced Chronic Kidney Disease. Calcif Tissue Int 115:516\u2013524. https:\/\/doi.org\/10.1007\/s00223-024-01275-4","journal-title":"Calcif Tissue Int"},{"key":"2955_CR96","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000863","author":"D Cejka","year":"2025","unstructured":"Cejka D, Haarhaus M, Pasch A, Smith ER (2025) Calciprotein Particles and the Mineral Buffering System of Blood. J Am Soc Nephrol. https:\/\/doi.org\/10.1681\/ASN.0000000863","journal-title":"J Am Soc Nephrol"},{"key":"2955_CR97","doi-asserted-by":"publisher","first-page":"00","DOI":"10.1161\/ATVBAHA.117.310578","volume":"38","author":"C Viegas","year":"2018","unstructured":"Viegas C, Santos L, Macedo A et al (2018) Chronic Kidney Disease Circulating Calciprotein Particles and Extracellular Vesicles Promote Vascular Calcification A Role for GRP (Gla-Rich Protein). Arterioscler Thromb Vasc Biol 38:00\u201300. https:\/\/doi.org\/10.1161\/ATVBAHA.117.310578","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2955_CR98","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/ki.2013.521","volume":"85","author":"KA Lomashvili","year":"2014","unstructured":"Lomashvili KA, Narisawa S, Mill\u00e1n JL, O\u2019Neill WC (2014) Vascular calcification is dependent on plasma levels of pyrophosphate. Kidney Int 85:1351\u20131356. https:\/\/doi.org\/10.1038\/ki.2013.521","journal-title":"Kidney Int"},{"key":"2955_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00154","volume":"7","author":"S Roumeliotis","year":"2020","unstructured":"Roumeliotis S, Dounousi E, Salmas M, Eleftheriadis T, Liakopoulos V (2020) Vascular Calcification in Chronic Kidney Disease: The Role of Vitamin K- Dependent Matrix Gla Protein. Front Med (Lausanne) 7:154. https:\/\/doi.org\/10.3389\/fmed.2020.00154","journal-title":"Front Med (Lausanne)"},{"key":"2955_CR100","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00424-025-03083-7","volume":"477","author":"ER Smith","year":"2025","unstructured":"Smith ER, Holt SG (2025) The formation and function of calciprotein particles. Pflugers Arch 477:753\u2013772. https:\/\/doi.org\/10.1007\/s00424-025-03083-7","journal-title":"Pflugers Arch"},{"key":"2955_CR101","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ajt.2022.12.015","volume":"23","author":"C Eelderink","year":"2023","unstructured":"Eelderink C, Kremer D, Riphagen IJ et al (2023) Effect of vitamin K supplementation on serum calcification propensity and arterial stiffness in vitamin K-deficient kidney transplant recipients: A double-blind, randomized, placebo-controlled clinical trial. Am J Transplant 23:520\u2013530. https:\/\/doi.org\/10.1016\/j.ajt.2022.12.015","journal-title":"Am J Transplant"},{"key":"2955_CR102","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/ndt\/gfac191","volume":"38","author":"RM Holden","year":"2023","unstructured":"Holden RM, Booth SL, Zimmerman D et al (2023) Inhibit progression of coronary artery calcification with vitamin K in hemodialysis patients (the iPACK-HD study): a randomized, placebo-controlled multi-center, pilot trial. Nephrol Dial Transplant 38:746\u2013756. https:\/\/doi.org\/10.1093\/ndt\/gfac191","journal-title":"Nephrol Dial Transplant"},{"key":"2955_CR103","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-025-05702-z","author":"L Feenstra","year":"2025","unstructured":"Feenstra L, Zeper LW, van de Langenberg B et al (2025) Calciprotein particle-activated endothelial cells aggravate smooth muscle cell calcification via paracrine signalling. Cell Mol Life Sci. https:\/\/doi.org\/10.1007\/s00018-025-05702-z","journal-title":"Cell Mol Life Sci"},{"key":"2955_CR104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019595","volume":"6","author":"D Zhu","year":"2011","unstructured":"Zhu D, Mackenzie NCW, Mill\u00e1n JL, Farquharson C, MacRae VE (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 6:e19595. https:\/\/doi.org\/10.1371\/journal.pone.0019595","journal-title":"PLoS One"},{"key":"2955_CR105","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jbmr.4203","volume":"36","author":"ML Mace","year":"2021","unstructured":"Mace ML, Gravesen E, Nordholm A et al (2021) Chronic Kidney Disease\u2013Induced Vascular Calcification Impairs Bone Metabolism. J Bone Min Res 36:510\u2013522. https:\/\/doi.org\/10.1002\/jbmr.4203","journal-title":"J Bone Min Res"},{"key":"2955_CR106","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1291\/hypres.27.47","volume":"27","author":"K Nitta","year":"2004","unstructured":"Nitta K, Akiba T, Uchida K et al (2004) Left Ventricular Hypertrophy Is Associated with Arterial Stiffness and Vascular Calcification in Hemodialysis Patients. Hypertens Res 27:47\u201352","journal-title":"Hypertens Res"},{"key":"2955_CR107","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Investig 121:4393\u20134408. https:\/\/doi.org\/10.1172\/JCI46122","journal-title":"J Clin Investig"},{"key":"2955_CR108","doi-asserted-by":"publisher","first-page":"e2310909","DOI":"10.1001\/jamanetworkopen.2023.10909","volume":"6","author":"H Zhang","year":"2023","unstructured":"Zhang H, Li G, Yu X et al (2023) Progression of Vascular Calcification and Clinical Outcomes in Patients Receiving Maintenance Dialysis. JAMA Netw Open 6:e2310909. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.10909","journal-title":"JAMA Netw Open"},{"key":"2955_CR109","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/ndt\/gfad100","volume":"38","author":"L Magagnoli","year":"2023","unstructured":"Magagnoli L, Cozzolino M, Caskey FJ et al (2023) Association between CKD-MBD and mortality in older patients with advanced CKD\u2014results from the EQUAL study. Nephrol Dial Transpl 38:2562\u20132575. https:\/\/doi.org\/10.1093\/ndt\/gfad100","journal-title":"Nephrol Dial Transpl"},{"key":"2955_CR110","doi-asserted-by":"publisher","first-page":"sfa338","DOI":"10.1093\/ckj\/sfaf338","volume":"18","author":"S Huish","year":"2025","unstructured":"Huish S, Moore S, Alfieri C et al (2025) Calciphylaxis diagnosis, management and future directions: a comprehensive update on behalf of the European Renal Association CKD-MBD Working Group. Clin Kidney J 18:sfa338. https:\/\/doi.org\/10.1093\/ckj\/sfaf338","journal-title":"Clin Kidney J"},{"key":"2955_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/nu13062065","volume":"13","author":"J Rysz","year":"2021","unstructured":"Rysz J, Franczyk B, Rokicki R, Gluba-brz\u00f3zka A (2021) The influence of dietary interventions on chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Nutrients. 13:2065. https:\/\/doi.org\/10.3390\/nu13062065","journal-title":"Nutrients."},{"key":"2955_CR112","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.nefro.2020.11.012","volume":"42","author":"S Sharma","year":"2022","unstructured":"Sharma S, Gupta A (2022) Adynamic bone disease: Revisited. Nefrologia 42:8\u201314. https:\/\/doi.org\/10.1016\/j.nefro.2020.11.012","journal-title":"Nefrologia"},{"key":"2955_CR113","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/ndt\/gfae139","volume":"40","author":"JE Kim","year":"2025","unstructured":"Kim JE, Park J, Jang Y et al (2025) Oral phosphate binders and incident osteoporotic fracture in patients on dialysis. Nephrol Dial Transpl 40:329\u2013340. https:\/\/doi.org\/10.1093\/ndt\/gfae139","journal-title":"Nephrol Dial Transpl"},{"issue":"Suppl 113","key":"2955_CR114","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBD). Kidney Int 76(Suppl 113):S1\u2013S130. https:\/\/doi.org\/10.1038\/ki.2009.188","journal-title":"Kidney Int"},{"key":"2955_CR115","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/00365513.2025.2512998","volume":"85","author":"IM N\u00f8rum Wigh","year":"2025","unstructured":"N\u00f8rum Wigh IM, Aagaard Thomsen AK, Jensen JD, J\u00f8rgensen HS, Andersen SL (2025) Parathyroid hormone using second and third generation assays in patients with various stages of chronic kidney disease. Scand J Clin Lab Invest 85:313\u2013320. https:\/\/doi.org\/10.1080\/00365513.2025.2512998","journal-title":"Scand J Clin Lab Invest"},{"key":"2955_CR116","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.4102\/ajlm","volume":"14","author":"N Nhlapo","year":"2025","unstructured":"Nhlapo N, Jacob D, Khoza S, Maphayi MR, Maphayi M (2025) Comparisson of second and third-generation parathyroid hormone assays at a tertiary hospital in South Africa. Afr J Lab Med 14:2002\u20132025. https:\/\/doi.org\/10.4102\/ajlm","journal-title":"Afr J Lab Med"},{"key":"2955_CR117","doi-asserted-by":"publisher","first-page":"e928301","DOI":"10.12659\/MSM.928301","volume":"26","author":"M W\u00f3jtowicz","year":"2020","unstructured":"W\u00f3jtowicz M, Piechota W, Wa\u0144kowicz Z, Smoszna J, Niemczyk S (2020) Comparison of second- and third-generation parathyroid hormone test results in patients with chronic kidney disease. Med Sci Monit 26:e928301. https:\/\/doi.org\/10.12659\/MSM.928301","journal-title":"Med Sci Monit"},{"key":"2955_CR118","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.metabol.2013.05.007","volume":"62","author":"MH Gannag\u00e9-Yared","year":"2013","unstructured":"Gannag\u00e9-Yared MH, Far\u00e8s C, Ibrahim T, Rahal ZA, Elias M, Chelala D (2013) Comparison between a second and a third-generation parathyroid hormone assay in hemodialysis patients. Metabolism 62:1416\u20131422. https:\/\/doi.org\/10.1016\/j.metabol.2013.05.007","journal-title":"Metabolism"},{"key":"2955_CR119","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3343\/alm.2017.37.5.381","volume":"37","author":"Y Einbinder","year":"2017","unstructured":"Einbinder Y, Benchetrit S, Golan E, Zitman-Gal T (2017) Comparison of intact PTH and bio-intact PTH assays among non-dialysis dependent chronic kidney disease patients. Ann Lab Med 37:381\u2013387. https:\/\/doi.org\/10.3343\/alm.2017.37.5.381","journal-title":"Ann Lab Med"},{"key":"2955_CR120","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/ndt\/gfae293","volume":"40","author":"HS J\u00f8rgensen","year":"2025","unstructured":"J\u00f8rgensen HS, Vervloet M, Cavalier E et al (2025) The role of nutritional vitamin D in chronic kidney disease\u2013mineral and bone disorder in children and adults with chronic kidney disease, on dialysis, and after kidney transplantation\u2014a European consensus statement. Nephrol Dial Transpl 40:797\u2013822. https:\/\/doi.org\/10.1093\/ndt\/gfae293","journal-title":"Nephrol Dial Transpl"},{"key":"2955_CR121","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000499187","volume":"49","author":"SA Strugnell","year":"2019","unstructured":"Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW (2019) Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. Am J Nephrol 49:284\u2013293. https:\/\/doi.org\/10.1159\/000499187","journal-title":"Am J Nephrol"},{"key":"2955_CR122","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40620-015-0186-0","volume":"29","author":"JL Ennis","year":"2016","unstructured":"Ennis JL, Worcester EM, Coe FL, Sprague SM (2016) Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol 29:63\u201370. https:\/\/doi.org\/10.1007\/s40620-015-0186-0","journal-title":"J Nephrol"},{"key":"2955_CR123","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40620-020-00715-2","volume":"33","author":"A Bouma-de Krijger","year":"2020","unstructured":"Bouma-de Krijger A, Vervloet MG (2020) Fibroblast growth factor 23: are we ready to use it in clinical practice? J Nephrol 33:509\u2013527. https:\/\/doi.org\/10.1007\/s40620-020-00715-2","journal-title":"J Nephrol"},{"key":"2955_CR124","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bone.2016.10.012","volume":"96","author":"AG Costa","year":"2017","unstructured":"Costa AG, Cremers S, Bilezikian JP (2017) Sclerostin measurement in human disease: validity and current limitations. Bone 96:24\u201328. https:\/\/doi.org\/10.1016\/j.bone.2016.10.012","journal-title":"Bone"},{"key":"2955_CR125","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.ecl.2017.07.008","volume":"46","author":"L Zand","year":"2017","unstructured":"Zand L, Kumar R (2017) The use of vitamin D metabolites and analogues in the treatment of chronic kidney disease. Endocrinol Metab Clin North Am 46:983\u20131007. https:\/\/doi.org\/10.1016\/j.ecl.2017.07.008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2955_CR126","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1007\/s40618-024-02383-6","volume":"47","author":"Y Lin","year":"2024","unstructured":"Lin Y, Xie C, Zhang Y et al (2024) Association of serum 25-hydroxyvitamin D with cardiovascular mortality and kidney outcome in patients with early stages of CKD. J Endocrinol Invest 47:2745\u20132755. https:\/\/doi.org\/10.1007\/s40618-024-02383-6","journal-title":"J Endocrinol Invest"},{"key":"2955_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-02993-3","volume":"23","author":"MJ Germain","year":"2022","unstructured":"Germain MJ, Paul SK, Fadda G et al (2022) Real-world assessment: effectiveness and safety of extended release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients. BMC Nephrol 23:362. https:\/\/doi.org\/10.1186\/s12882-022-02993-3","journal-title":"BMC Nephrol"},{"key":"2955_CR128","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000450766","volume":"44","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Crawford PW, Melnick JZ et al (2016) Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol 44:316\u2013325. https:\/\/doi.org\/10.1159\/000450766","journal-title":"Am J Nephrol"},{"key":"2955_CR129","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfx059","volume":"33","author":"PA Westerberg","year":"2018","unstructured":"Westerberg PA, Sterner G, Ljunggren \u00d6 et al (2018) High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD stages 3\u20134: results of a 12-week double-blind, randomized, controlled study. Nephrol Dial Transplant 33:466\u2013471. https:\/\/doi.org\/10.1093\/ndt\/gfx059","journal-title":"Nephrol Dial Transplant"},{"key":"2955_CR130","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/13696998.2019.1693385","volume":"23","author":"K Kalantar-Zadeh","year":"2020","unstructured":"Kalantar-Zadeh K, Hollenbeak CS, Arguello R, Snyder S, Ashfaq A (2020) The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3\u20134 CKD. J Med Econ 23:308\u2013315. https:\/\/doi.org\/10.1080\/13696998.2019.1693385","journal-title":"J Med Econ"},{"key":"2955_CR131","doi-asserted-by":"publisher","first-page":"840","DOI":"10.20452\/pamw.4124","volume":"127","author":"J Zawierucha","year":"2017","unstructured":"Zawierucha J, Ma\u0142yszko J, Ma\u0142yszko JS, Prystacki T, Marcinkowsky W, Dryl-Rydzy\u0144ska T (2017) Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients. Pol Arch Intern Med 127:840\u2013845. https:\/\/doi.org\/10.20452\/pamw.4124","journal-title":"Pol Arch Intern Med"},{"key":"2955_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102057","volume":"18","author":"N Oberm\u00fcller","year":"2017","unstructured":"Oberm\u00fcller N, Rosenkranz AR, M\u00fcller HW et al (2017) Long-term therapy outcomes when treating chronic kidney disease patients with paricalcitol in German and Austrian clinical practice (TOP study). Int J Mol Sci 18:2057. https:\/\/doi.org\/10.3390\/ijms18102057","journal-title":"Int J Mol Sci"},{"key":"2955_CR133","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.hjc.2017.12.010","volume":"60","author":"M Giakoumis","year":"2019","unstructured":"Giakoumis M, Tsioufis C, Dimitriadis K et al (2019) Effects of oral paricalcitol therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism. Hellenic Journal of Cardiology 60:108\u2013113. https:\/\/doi.org\/10.1016\/j.hjc.2017.12.010","journal-title":"Hellenic Journal of Cardiology"},{"key":"2955_CR134","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1002\/jbmr.4440","volume":"36","author":"M Fusaro","year":"2021","unstructured":"Fusaro M, Cianciolo G, Tripepi G et al (2021) Oral calcitriol use, vertebral fractures, and vitamin K in hemodialysis patients: a cross-sectional study. J Bone Miner Res 36:2361\u20132370. https:\/\/doi.org\/10.1002\/jbmr.4440","journal-title":"J Bone Miner Res"},{"key":"2955_CR135","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/ki.2014.349","volume":"87","author":"GJ Behets","year":"2015","unstructured":"Behets GJ, Spasovski G, Sterling LR et al (2015) Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87:846\u2013856. https:\/\/doi.org\/10.1038\/ki.2014.349","journal-title":"Kidney Int"},{"key":"2955_CR136","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000496808","volume":"142","author":"S Okuno","year":"2019","unstructured":"Okuno S, Inaba M, Ishimura E et al (2019) Effects of long-term cinacalcet administration on parathyroid gland in hemodialysis patients with secondary hyperparathyroidism. Nephron 142:106\u2013113. https:\/\/doi.org\/10.1159\/000496808","journal-title":"Nephron"},{"key":"2955_CR137","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/0886022X.2018.1562356","volume":"41","author":"P Susantitaphong","year":"2019","unstructured":"Susantitaphong P, Vadcharavivad S, Susomboon T et al (2019) The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism. Ren Fail 41:326\u2013333. https:\/\/doi.org\/10.1080\/0886022X.2018.1562356","journal-title":"Ren Fail"},{"key":"2955_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20552-5","volume":"8","author":"M Evans","year":"2018","unstructured":"Evans M, Methven S, Gasparini A et al (2018) Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism. Sci Rep 8:2103. https:\/\/doi.org\/10.1038\/s41598-018-20552-5","journal-title":"Sci Rep"},{"key":"2955_CR139","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.03591006","volume":"3","author":"P Messa","year":"2008","unstructured":"Messa P, Mac\u00e1rio F, Yaqoob M et al (2008) The OPTIMA study: Assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3:36\u201345. https:\/\/doi.org\/10.2215\/CJN.03591006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2955_CR140","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10157-020-01936-2","volume":"25","author":"K Yokoyama","year":"2021","unstructured":"Yokoyama K, Fukagawa M, Shigematsu T et al (2021) Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan. Clin Exp Nephrol 25:66\u201379. https:\/\/doi.org\/10.1007\/s10157-020-01936-2","journal-title":"Clin Exp Nephrol"},{"key":"2955_CR141","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/ndt\/gfw408","volume":"32","author":"M Fukagawa","year":"2017","unstructured":"Fukagawa M, Yokoyama K, Shigematsu T et al (2017) A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transpl 32:1723\u20131730. https:\/\/doi.org\/10.1093\/ndt\/gfw408","journal-title":"Nephrol Dial Transpl"},{"key":"2955_CR142","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/ndt\/gfz039","volume":"35","author":"DA Bushinsky","year":"2020","unstructured":"Bushinsky DA, Chertow GM, Cheng S et al (2020) One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrol Dial Transpl 35:1769\u20131778. https:\/\/doi.org\/10.1093\/ndt\/gfz039","journal-title":"Nephrol Dial Transpl"},{"key":"2955_CR143","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.ajkd.2021.05.020","volume":"79","author":"A Karaboyas","year":"2022","unstructured":"Karaboyas A, Muenz D, Fuller DS et al (2022) Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease\u2013Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients. Am J Kidney Dis 79:362\u2013373. https:\/\/doi.org\/10.1053\/j.ajkd.2021.05.020","journal-title":"Am J Kidney Dis"},{"key":"2955_CR144","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10157-019-01692-y","volume":"23","author":"K Tsuruya","year":"2019","unstructured":"Tsuruya K, Shimazaki R, Fukagawa M et al (2019) Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. Clin Exp Nephrol 23:739\u2013748. https:\/\/doi.org\/10.1007\/s10157-019-01692-y","journal-title":"Clin Exp Nephrol"},{"key":"2955_CR145","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/j.clinthera.2018.10.016","volume":"40","author":"T Shigematsu","year":"2018","unstructured":"Shigematsu T, Fukagawa M, Yokoyama K et al (2018) Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study. Clin Ther 40:2099\u20132111. https:\/\/doi.org\/10.1016\/j.clinthera.2018.10.016","journal-title":"Clin Ther"},{"key":"2955_CR146","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","volume":"132","author":"SM Moe","year":"2015","unstructured":"Moe SM, Chertow GM, Parfrey PS et al (2015) Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 132:27\u201339. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013876","journal-title":"Circulation"},{"key":"2955_CR147","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.kint.2017.05.003","volume":"92","author":"C Ritter","year":"2017","unstructured":"Ritter C, Miller B, Coyne DW et al (2017) Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease. Kidney Int 92:1217\u20131222. https:\/\/doi.org\/10.1016\/j.kint.2017.05.003","journal-title":"Kidney Int"},{"key":"2955_CR148","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1159\/000510360","volume":"51","author":"MD Danese","year":"2020","unstructured":"Danese MD, Lubeck D, Belozeroff V et al (2020) Real world use and effects of calcimimetics in treating mineral and bone disorder in hemodialysis patients. Am J Nephrol 51:815\u2013822. https:\/\/doi.org\/10.1159\/000510360","journal-title":"Am J Nephrol"},{"key":"2955_CR149","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1053\/j.ajkd.2020.02.439","volume":"76","author":"SC Palmer","year":"2020","unstructured":"Palmer SC, Mavridis D, Johnson DW, Tonelli M, Ruospo M, Strippoli GFM (2020) Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: a systematic review and network meta-analysis. Am J Kidney Dis 76:321\u2013330. https:\/\/doi.org\/10.1053\/j.ajkd.2020.02.439","journal-title":"Am J Kidney Dis"},{"key":"2955_CR150","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","volume":"94","author":"M Fukagawa","year":"2018","unstructured":"Fukagawa M, Shimazaki R, Akizawa T (2018) Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 94:818\u2013825. https:\/\/doi.org\/10.1016\/j.kint.2018.05.013","journal-title":"Kidney Int"},{"key":"2955_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97587-8","volume":"11","author":"J Ngamkam","year":"2021","unstructured":"Ngamkam J, Vadcharavivad S, Areepium N et al (2021) The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism. Sci Rep 11:18006. https:\/\/doi.org\/10.1038\/s41598-021-97587-8","journal-title":"Sci Rep"},{"key":"2955_CR152","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1681\/ASN.2021060825","volume":"33","author":"WG Goodman","year":"2022","unstructured":"Goodman WG, Ward DT, Martin KJ et al (2022) Activation of the calcium receptor by calcimimetic agents is preserved despite modest attenuating effects of hyperphosphatemia. J Am Soc Nephrol 33:201\u2013212. https:\/\/doi.org\/10.1681\/ASN.2021060825","journal-title":"J Am Soc Nephrol"},{"key":"2955_CR153","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1245\/s10434-016-5450-6","volume":"24","author":"WY van der Plas","year":"2017","unstructured":"van der Plas WY, Engelsman AF, \u00d6zyilmaz A et al (2017) Impact of the introduction of calcimimetics on timing of parathyroidectomy in secondary and tertiary hyperparathyroidism. Ann Surg Oncol 24:15\u201322. https:\/\/doi.org\/10.1245\/s10434-016-5450-6","journal-title":"Ann Surg Oncol"},{"key":"2955_CR154","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","volume":"68","author":"J Cunningham","year":"2005","unstructured":"Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793\u20131800","journal-title":"Kidney Int"},{"key":"2955_CR155","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1681\/ASN.2014040414","volume":"26","author":"SM Moe","year":"2015","unstructured":"Moe SM, Abdalla S, Chertow GM et al (2015) Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol 26:1466\u20131475. https:\/\/doi.org\/10.1681\/ASN.2014040414","journal-title":"J Am Soc Nephrol"},{"key":"2955_CR156","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-012-0665-8","volume":"17","author":"Y Tsuruta","year":"2013","unstructured":"Tsuruta Y, Okano K, Kikuchi K, Tsuruta Y, Akiba T, Nitta K (2013) Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 17:120\u2013126. https:\/\/doi.org\/10.1007\/s10157-012-0665-8","journal-title":"Clin Exp Nephrol"},{"key":"2955_CR157","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"The EVOLVE Trial Investigators","year":"2012","unstructured":"The EVOLVE Trial Investigators (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Eng J Med 367:2482\u20132494. https:\/\/doi.org\/10.1056\/NEJMoa1205624","journal-title":"N Eng J Med"},{"key":"2955_CR158","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001363","volume":"3","author":"DC Wheeler","year":"2014","unstructured":"Wheeler DC, London GM, Parfrey PS et al (2014) Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial. Journal of the American Heart Association 3:e001363. https:\/\/doi.org\/10.1161\/JAHA.114.001363","journal-title":"Journal of the American Heart Association"},{"key":"2955_CR159","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejim.2017.05.002","volume":"42","author":"C Friedl","year":"2017","unstructured":"Friedl C, Reibnegger G, Kramar R et al (2017) Mortality in dialysis patients with cinacalcet use: a large observational registry study. Eur J Intern Med 42:89\u201395. https:\/\/doi.org\/10.1016\/j.ejim.2017.05.002","journal-title":"Eur J Intern Med"},{"key":"2955_CR160","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2215\/CJN.16601020","volume":"16","author":"T Shoji","year":"2021","unstructured":"Shoji T, Nakatani S, Kabata D et al (2021) Comparative effects of etelcalcetide and maxacalcitol on serum calcification propensity in secondary hyperparathyroidism a randomized clinical trial. Clin J Am Soc Nephrol 16:599\u2013612. https:\/\/doi.org\/10.2215\/CJN.16601020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2955_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02312-2","volume":"22","author":"H Eddington","year":"2021","unstructured":"Eddington H, Chinnadurai R, Alderson H et al (2021) A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism. BMC Nephrol 22:106. https:\/\/doi.org\/10.1186\/s12882-021-02312-2","journal-title":"BMC Nephrol"},{"key":"2955_CR162","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU et al (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26:1327\u20131339. https:\/\/doi.org\/10.1093\/ndt\/gfq725","journal-title":"Nephrol Dial Transplant"},{"key":"2955_CR163","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.surg.2020.08.014","volume":"169","author":"W van der Plas","year":"2021","unstructured":"van der Plas W, Kruijff S, Sidhu SB, Delbridge LW, Sywak MS, Engelsman AF (2021) Parathyroidectomy for patients with secondary hyperparathyroidism in a changing landscape for the management of end-stage renal disease. Surg (United States) 169:275\u2013281. https:\/\/doi.org\/10.1016\/j.surg.2020.08.014","journal-title":"Surg (United States)"},{"key":"2955_CR164","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/0886022X.2019.1666724","volume":"41","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Lu Y, Feng S, Zhan Z, Shen H (2019) Evaluation of laboratory parameters and symptoms after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Ren Fail 41:921\u2013929. https:\/\/doi.org\/10.1080\/0886022X.2019.1666724","journal-title":"Ren Fail"},{"key":"2955_CR165","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/0886022X.2021.2016445","volume":"44","author":"S Zhao","year":"2022","unstructured":"Zhao S, Gan W, Xie W et al (2022) A single-center experience of parathyroidectomy in 1500 cases for secondary hyperparathyroidism: a retrospective study. Ren Fail 44:23\u201329. https:\/\/doi.org\/10.1080\/0886022X.2021.2016445","journal-title":"Ren Fail"},{"key":"2955_CR166","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.surg.2018.06.032","volume":"164","author":"WA Filho","year":"2018","unstructured":"Filho WA, van der Plas WY, Brescia MDG et al (2018) Quality of life after surgery in secondary hyperparathyroidism, comparing subtotal parathyroidectomy with total parathyroidectomy with immediate parathyroid autograft: Prospective randomized trial. Surg (United States) 164:978\u2013985. https:\/\/doi.org\/10.1016\/j.surg.2018.06.032","journal-title":"Surg (United States)"},{"key":"2955_CR167","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ijsu.2017.06.029","volume":"44","author":"ME Liu","year":"2017","unstructured":"Liu ME, Qiu NC, Zha SL et al (2017) To assess the effects of parathyroidectomy (TPTX versus TPTX\u2009+\u2009AT) for Secondary Hyperparathyroidism in chronic renal failure: A Systematic Review and Meta-Analysis. Int J Surg 44:353\u2013362. https:\/\/doi.org\/10.1016\/j.ijsu.2017.06.029","journal-title":"Int J Surg"},{"key":"2955_CR168","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00268-022-06439-7","volume":"46","author":"L Alvarado","year":"2022","unstructured":"Alvarado L, Sharma N, Lerma R et al (2022) Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients. World J Surg 46:813\u2013819. https:\/\/doi.org\/10.1007\/s00268-022-06439-7","journal-title":"World J Surg"},{"key":"2955_CR169","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s40620-023-01658-0","volume":"36","author":"L Tartaglione","year":"2023","unstructured":"Tartaglione L, Rotondi S, Aucella F et al (2023) Parathyroidectomy and survival in a cohort of Italian dialysis patients: results of a multicenter, observational, prospective study. J Nephrol 36:1947\u20131955. https:\/\/doi.org\/10.1007\/s40620-023-01658-0","journal-title":"J Nephrol"},{"key":"2955_CR170","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3803\/EnM.2019.34.4.367","volume":"34","author":"MMA Elgawwad El-Kholey","year":"2019","unstructured":"Elgawwad El-Kholey MMA, El-Said Ibrahim G, Elshahat OI, El-Kannishy G (2019) Impact of subtotal parathyroidectomy on clinical parameters and quality of life in hemodialysis patients with secondary hyperparathyroidism. Endocrinol Metab 34:367\u2013373. https:\/\/doi.org\/10.3803\/EnM.2019.34.4.367","journal-title":"Endocrinol Metab"},{"key":"2955_CR171","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12882-018-0934-1","volume":"19","author":"L Fang","year":"2018","unstructured":"Fang L, Wu J, Luo J et al (2018) Changes in bone mineral density after total parathyroidectomy without autotransplantation in the end-stage renal disease patients with secondary hyperparathyroidism. BMC Nephrol 19:142. https:\/\/doi.org\/10.1186\/s12882-018-0934-1","journal-title":"BMC Nephrol"},{"key":"2955_CR172","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1186\/s12882-020-02139-3","volume":"21","author":"S Chen","year":"2020","unstructured":"Chen S, Sheng K, Shen Y et al (2020) Impact of parathyroidectomy on left ventricular function in end stage renal disease patients. BMC Nephrol 21:479. https:\/\/doi.org\/10.1186\/s12882-020-02139-3","journal-title":"BMC Nephrol"},{"key":"2955_CR173","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.surg.2020.06.012","volume":"169","author":"C McManus","year":"2021","unstructured":"McManus C, Oh A, Lee JA, Hur C, Kuo JH (2021) Timing of parathyroidectomy for tertiary hyperparathyroidism with end-stage renal disease: A cost-effectiveness analysis. Surg (United States) 169:94\u2013101. https:\/\/doi.org\/10.1016\/j.surg.2020.06.012","journal-title":"Surg (United States)"},{"key":"2955_CR174","doi-asserted-by":"publisher","first-page":"E366","DOI":"10.1097\/TP.0000000000003653","volume":"105","author":"A Mathur","year":"2021","unstructured":"Mathur A, Sutton W, Ahn JYB et al (2021) Association between treatment of secondary hyperparathyroidism and posttransplant outcomes. Transplantation 105:E366\u2013E374. https:\/\/doi.org\/10.1097\/TP.0000000000003653","journal-title":"Transplantation"},{"key":"2955_CR175","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.surg.2017.09.005","volume":"163","author":"R Albuquerque","year":"2018","unstructured":"Albuquerque R, de FC, Carbonara CEM, Martin R, de CT et al (2018) Parathyroidectomy in patients with chronic kidney disease: Impacts of different techniques on the biochemical and clinical evolution of secondary hyperparathyroidism. Surg (United States) 163:381\u2013387. https:\/\/doi.org\/10.1016\/j.surg.2017.09.005","journal-title":"Surg (United States)"},{"key":"2955_CR176","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.surg.2018.04.076","volume":"165","author":"E Isaksson","year":"2019","unstructured":"Isaksson E, Ivarsson K, Akaberi S et al (2019) Total versus subtotal parathyroidectomy for secondary hyperparathyroidism. Surg (United States) 165:142\u2013150. https:\/\/doi.org\/10.1016\/j.surg.2018.04.076","journal-title":"Surg (United States)"},{"key":"2955_CR177","doi-asserted-by":"publisher","first-page":"w20160","DOI":"10.4414\/smw.2019.20160","volume":"149","author":"L Steffen","year":"2019","unstructured":"Steffen L, Moffa G, M\u00fcller PC, Oertli D (2019) Secondary hyperparathyroidism: recurrence after total parathyroidectomy with autotransplantation. Swiss Med Wkly 149:w20160. https:\/\/doi.org\/10.4414\/smw.2019.20160","journal-title":"Swiss Med Wkly"},{"key":"2955_CR178","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/nep.12801","volume":"22","author":"J Chen","year":"2017","unstructured":"Chen J, Jia X, Kong X, Wang Z, Cui M, Xu D (2017) Total parathyroidectomy with autotransplantation versus subtotal parathyroidectomy for renal hyperparathyroidism: A systematic review and meta-analysis. Nephrol (Carlton) 22:388\u2013396. https:\/\/doi.org\/10.1111\/nep.12801","journal-title":"Nephrol (Carlton)"},{"key":"2955_CR179","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s10157-018-1543-9","volume":"22","author":"E Isaksson","year":"2018","unstructured":"Isaksson E, Almquist M, Seeberger A, Sterner G (2018) Is low pre-transplant parathyroid hormone a risk marker for cardiovascular disease in long-term follow-up of renal transplant recipients? Clin Exp Nephrol 22:1188\u20131197. https:\/\/doi.org\/10.1007\/s10157-018-1543-9","journal-title":"Clin Exp Nephrol"},{"key":"2955_CR180","doi-asserted-by":"publisher","first-page":"115048","DOI":"10.1016\/j.bone.2019.115048","volume":"129","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Makras P, Tournis S, Anastasilakis AD (2019) Off-label uses of denosumab in metabolic bone diseases. Bone 129:115048. https:\/\/doi.org\/10.1016\/j.bone.2019.115048","journal-title":"Bone"},{"key":"2955_CR181","doi-asserted-by":"publisher","first-page":"822178","DOI":"10.3389\/fphar.2022.822178","volume":"13","author":"CH Chen","year":"2022","unstructured":"Chen CH, Lo WC, Hu P et al (2022) Efficacy of Osteoporosis Medications for Patients With Chronic Kidney Disease: An Updated Systematic Review and Network Meta-Analysis. Front Pharmacol 13:822178. https:\/\/doi.org\/10.3389\/fphar.2022.822178","journal-title":"Front Pharmacol"},{"key":"2955_CR182","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18:59\u201368. https:\/\/doi.org\/10.1007\/s00198-006-0189-8","journal-title":"Osteoporos Int"},{"key":"2955_CR183","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1359\/jbmr.070112","volume":"22","author":"SA Jamal","year":"2007","unstructured":"Jamal SA, Bauer DC, Ensrud KE et al (2007) Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial. J Bone Min Res 22:503\u2013508. https:\/\/doi.org\/10.1359\/jbmr.070112","journal-title":"J Bone Min Res"},{"key":"2955_CR184","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren \u00d6, Stehman-Breen C et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Min Res 26:1829\u20131835. https:\/\/doi.org\/10.1002\/jbmr.403","journal-title":"J Bone Min Res"},{"key":"2955_CR185","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1681\/ASN.2007050555","volume":"19","author":"A Ishani","year":"2008","unstructured":"Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE (2008) The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 19:1430\u20131438. https:\/\/doi.org\/10.1681\/ASN.2007050555","journal-title":"J Am Soc Nephrol"},{"key":"2955_CR186","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1080\/03007995.2019.1656955","volume":"35","author":"JP Bilezikian","year":"2019","unstructured":"Bilezikian JP, Hattersley G, Mitlak BH et al (2019) Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Curr Med Res Opin 35:2097\u20132102. https:\/\/doi.org\/10.1080\/03007995.2019.1656955","journal-title":"Curr Med Res Opin"},{"key":"2955_CR187","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jbmr.4563","volume":"37","author":"PD Miller","year":"2022","unstructured":"Miller PD, Adachi JD, Albergaria BH et al (2022) Efficacy and Safety of Romosozumab Among Postmenopausal Women with Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. J Bone Min Res 37:1437\u20131445. https:\/\/doi.org\/10.1002\/jbmr.4563","journal-title":"J Bone Min Res"},{"key":"2955_CR188","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/hdi.13098","volume":"27","author":"Z Gu","year":"2023","unstructured":"Gu Z, Yang X, Wang Y, Gao J (2023) Effects of denosumab on bone mineral density and bone metabolism in patients with end-stage renal disease: A systematic review and meta\u2010analysis. Hemodial Int 27:352\u2013363. https:\/\/doi.org\/10.1111\/hdi.13098","journal-title":"Hemodial Int"},{"key":"2955_CR189","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.3676","volume":"34","author":"K Iseri","year":"2019","unstructured":"Iseri K, Watanabe M, Yoshikawa H et al (2019) Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial. J Bone Min Res 34:1014\u20131024. https:\/\/doi.org\/10.1002\/jbmr.3676","journal-title":"J Bone Min Res"},{"key":"2955_CR190","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1046\/j.1523-1755.2003.00005.x","volume":"63","author":"E Hern\u00e1ndez","year":"2003","unstructured":"Hern\u00e1ndez E, Valera R, Alonzo E et al (2003) Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 63:2269\u20132274. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00005.x","journal-title":"Kidney Int"},{"key":"2955_CR191","unstructured":"U.S. Food and Drug Administration (2025) Highlights of prescribing information: Fosamax., https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020560s070lbl.pdf"},{"key":"2955_CR192","unstructured":"European Medicines Agency (2025) Summary of product characteristics: Raloxifene teva., https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/raloxifene-teva"},{"key":"2955_CR193","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","volume":"39","author":"M Sato","year":"2021","unstructured":"Sato M, Inaba M, Yamada S, Emoto M, Ohno Y, Tsujimoto Y (2021) Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Min Metab 39:1082\u20131090. https:\/\/doi.org\/10.1007\/s00774-021-01253-y","journal-title":"J Bone Min Metab"},{"key":"2955_CR194","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00223-022-01031-6","volume":"112","author":"T Saito","year":"2022","unstructured":"Saito T, Mizobuchi M, Kato T et al (2022) One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study. Calcif Tissue Int 112:34\u201344. https:\/\/doi.org\/10.1007\/s00223-022-01031-6","journal-title":"Calcif Tissue Int"},{"key":"2955_CR195","unstructured":"U.S. Food and Drug Administration (2025) Highlights of prescribing information: Evenity. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761062s002lbl.pdf"},{"key":"2955_CR196","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000341864","volume":"36","author":"E Mitsopoulos","year":"2012","unstructured":"Mitsopoulos E, Ginikopoulou E, Economidou D et al (2012) Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: A pilot study. Am J Nephrol 36:238\u2013244. https:\/\/doi.org\/10.1159\/000341864","journal-title":"Am J Nephrol"},{"key":"2955_CR197","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5414\/CN110993","volume":"98","author":"HH Malluche","year":"2022","unstructured":"Malluche HH, Davenport DL, Monier-Faugere MC, Lima F (2022) Treatment of bone loss in CKD5D: Better survival in patients with non-high bone turnover. Clin Nephrol 98:219\u2013228. https:\/\/doi.org\/10.5414\/CN110993","journal-title":"Clin Nephrol"},{"key":"2955_CR198","unstructured":"European Medicines Agency (2025) Summary of product characteristics: Forsteo., https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/forsteo-epar-product-information_en.pdf"},{"key":"2955_CR199","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000316708","volume":"33","author":"D Cejka","year":"2010","unstructured":"Cejka D, Kodras K, Bader T, Haas M (2010) Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): A pilot study. Kidney Blood Press Res 33:221\u2013226. https:\/\/doi.org\/10.1159\/000316708","journal-title":"Kidney Blood Press Res"},{"key":"2955_CR200","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","volume":"27","author":"K Sumida","year":"2016","unstructured":"Sumida K, Ubara Y, Hoshino J et al (2016) Once weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int 27:1441\u20131450. https:\/\/doi.org\/10.1007\/s00198-015-3377-6","journal-title":"Osteoporos Int"},{"key":"2955_CR201","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/1744-9987.12867","volume":"24","author":"J Yamamoto","year":"2020","unstructured":"Yamamoto J, Nakazawa D, Nishio S et al (2020) Impact of Weekly Teriparatide on the Bone and Mineral Metabolism in Hemodialysis Patients With Relatively Low Serum Parathyroid Hormone: A Pilot Study. Ther Apher Dial 24:146\u2013153. https:\/\/doi.org\/10.1111\/1744-9987.12867","journal-title":"Ther Apher Dial"},{"key":"2955_CR202","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1111\/j.1600-6143.2008.02327.x","volume":"8","author":"D Cejka","year":"2008","unstructured":"Cejka D, Benesch T, Krestan C et al (2008) Effect of teriparatide on early bone loss after kidney transplantation. Am J Transpl 8:1864\u20131870. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02327.x","journal-title":"Am J Transpl"},{"key":"2955_CR203","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s11255-025-04383-8","volume":"57","author":"D Vetrano","year":"2025","unstructured":"Vetrano D, Aguanno F, Passaseo A et al (2025) Efficacy and safety of teriparatide in kidney transplant recipients with osteoporosis and low bone turnover: a real-world experience. Int Urol Nephrol 57:1965\u20131975. https:\/\/doi.org\/10.1007\/s11255-025-04383-8","journal-title":"Int Urol Nephrol"},{"key":"2955_CR204","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1053\/j.ajkd.2015.01.025","volume":"65","author":"P Palcu","year":"2015","unstructured":"Palcu P, Dion N, Ste-Marie LG et al (2015) Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: A case report. Am J Kidney Dis 65:933\u2013936. https:\/\/doi.org\/10.1053\/j.ajkd.2015.01.025","journal-title":"Am J Kidney Dis"},{"key":"2955_CR205","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/ckj\/sfv005","volume":"8","author":"P Giamalis","year":"2015","unstructured":"Giamalis P, Economidou D, Dimitriadis C, Memmos D, Papagianni A, Efstratiadis G (2015) Treatment of adynamic bone disease in a haemodialysis patient with teriparatide. Clin Kidney J 8:188\u2013190. https:\/\/doi.org\/10.1093\/ckj\/sfv005","journal-title":"Clin Kidney J"},{"key":"2955_CR206","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00198-016-3858-2","volume":"28","author":"A Fahrleitner-Pammer","year":"2017","unstructured":"Fahrleitner-Pammer A, Wagner D, Krisper P, Amrein K, Dimai H (2017) Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report. Osteoporos Int 28:1149\u20131152. https:\/\/doi.org\/10.1007\/s00198-016-3858-2","journal-title":"Osteoporos Int"},{"key":"2955_CR207","doi-asserted-by":"publisher","first-page":"e10176","DOI":"10.1002\/jbm4.10176","volume":"3","author":"J Peugh","year":"2019","unstructured":"Peugh J, Khalil A, Chan MR, Hansen KE (2019) Teriparatide Treatment for Hypercalcemia Associated with Adynamic Bone Disease. J Bone Min Res Plus 3:e10176. https:\/\/doi.org\/10.1002\/jbm4.10176","journal-title":"J Bone Min Res Plus"},{"key":"2955_CR208","doi-asserted-by":"publisher","first-page":"101639","DOI":"10.1016\/j.bonr.2022.101639","volume":"17","author":"M Ogata","year":"2022","unstructured":"Ogata M, Ushimaru S, Fujishima R, Sumi H, Shiizaki K, Tominaga N (2022) Romosozumab improves low bone mineral density in a postmenopausal woman undergoing chronic hemodialysis and treated with a calcium-sensing receptor agonist. Bone Rep 17:101639. https:\/\/doi.org\/10.1016\/j.bonr.2022.101639","journal-title":"Bone Rep"},{"key":"2955_CR209","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3390\/jcm13051462","volume":"13","author":"H Kim","year":"2024","unstructured":"Kim H, Lee EJ, Woo S, Rho S, Jung JY (2024) Effect of Denosumab on Bone Health, Vascular Calcification, and Health-Related Quality of Life in Hemodialysis Patients with Osteoporosis: A Prospective Observational Study. J Clin Med 13:1462. https:\/\/doi.org\/10.3390\/jcm13051462","journal-title":"J Clin Med"},{"key":"2955_CR210","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000535882","volume":"14","author":"CL Chen","year":"2024","unstructured":"Chen CL, Liou ES, Wu MT (2024) Denosumab Decreases Epicardial Adipose Tissue Attenuation in Dialysis Patients with Secondary Hyperparathyroidism and Low Bone Mass. Cardiorenal Med 14:113\u2013122. https:\/\/doi.org\/10.1159\/000535882","journal-title":"Cardiorenal Med"},{"key":"2955_CR211","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/jbmr\/zjaf093","volume":"40","author":"T Seto","year":"2025","unstructured":"Seto T, Yukata K, Fujii Z et al (2025) Denosumab associated with accelerated progression of abdominal aortic calcification among patients on dialysis. J Bone Miner Res 40:1351\u20131359. https:\/\/doi.org\/10.1093\/jbmr\/zjaf093","journal-title":"J Bone Miner Res"},{"key":"2955_CR212","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2021","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2021) Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. J Clin Endocrinol Metab 106:264\u2013281. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"key":"2955_CR213","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3803\/EnM.2024.2125","volume":"40","author":"J Ha","year":"2025","unstructured":"Ha J, Lee YJ, Kim J et al (2025) Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use. Endocrinol Metab 40:47\u201356. https:\/\/doi.org\/10.3803\/EnM.2024.2125","journal-title":"Endocrinol Metab"},{"key":"2955_CR214","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomized controlled trial. Lancet 386:1147\u20131155. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"},{"key":"2955_CR215","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/jbmr\/zjae179","volume":"40","author":"N Hong","year":"2025","unstructured":"Hong N, Shin S, Kim H, Cho SJ, Park JA, Rhee Y (2025) Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women. J Bone Miner Res 40:184\u2013192. https:\/\/doi.org\/10.1093\/jbmr\/zjae179","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02955-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02955-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02955-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:01:11Z","timestamp":1793397671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02955-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":215,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["2955"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02955-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.A.P. has received honoraria for advisory boards or lectures from Rafarm, Innovis, Elpen, UCB, ITF-Hellas. E.K. reports fees for lectures\/advisory boards and grants from ErKim, ITF Hellas, Novo-Nordisk, Ascendis, Astra-Zeneca, and Elpen. S.T. reports fees for lectures\/advisory boards from Amgen, Ascendis, AstraZeneca, Elpen, ITF-Hellas, Er-Kim, Genesis and UCB. A.V. reports fees for lectures from ErKim.\u00a0M.M. and E.P. declare that they have no relevant financial or non-financial interests to disclose.\u00a0S.A.P. is an Associate Editor of the Journal of Endocrinological Investigation","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}